Edition:
United Kingdom

Roche Holding AG (RO.S)

RO.S on Swiss Exchange

229.40CHF
22 May 2018
Change (% chg)

CHF0.20 (+0.09%)
Prev Close
CHF229.20
Open
CHF231.20
Day's High
CHF231.80
Day's Low
CHF228.60
Volume
18,071
Avg. Vol
31,399
52-wk High
CHF268.75
52-wk Low
CHF215.40

Select another date:

Thu, May 17 2018

Roche says has had no contact with Trump lawyer Cohen

ZURICH, May 17 Roche has had no contact with U.S. President Donald Trump's personal attorney Michael Cohen, the Swiss pharmaceuticals maker's Chief Executive said on Thursday.

Swiss stocks - Factors to watch on May 17

ZURICH, May 17 Here are some of the main factors that may affect Swiss stocks on Thursday:

Roche immunotherapy combination increases lung cancer survival - study

Roche's immunotherapy Tecentriq, given with its older drug Avastin and chemotherapy, improved survival of advanced lung cancer patients by about 30 percent over the combination without Tecentriq, according to interim results of a late stage trial released on Wednesday.

Roche immunotherapy combination increases lung cancer survival-study

May 16 Roche's immunotherapy Tecentriq, given with its older drug Avastin and chemotherapy, improved survival of advanced lung cancer patients by about 30 percent over the combination without Tecentriq, according to interim results of a late stage trial released on Wednesday.

BRIEF-FDA Approves Additional Claim For Roche Cobas Zika Test

* NEW CLAIM ALLOWS FOR STREAMLINED SCREENING OF POOLED BLOOD OR PLASMA DONATIONS Source text for Eikon: Further company coverage:

BRIEF-Roche Holding AG CEO Says Very Confident We Can Grow In Spite Of The Entry Of Biosimilars

* CEO SAYS CONFIDENT OF ROCHE'S ABILITY TO CONTINUE GROWTH BEYOND 2018 DESPITE BIOSIMILAR ENTRIES

BRIEF-Roche Expands Indication For Cobas EGFR Mutation Test V2 As Companion Diagnostic With Tagrisso

* ROCHE EXPANDS INDICATION FOR COBAS® EGFR MUTATION TEST V2 AS A COMPANION DIAGNOSTIC WITH TAGRISSO®

BRIEF-Roche Holding Receives FDA Clearance For Cobas® Ct/Ng For Cobas® 6800/8800 Systems

* ROCHE RECEIVES FDA CLEARANCE FOR COBAS® CT/NG FOR COBAS® 6800/8800 SYSTEMS Source text for Eikon: Further company coverage:

BRIEF-Roche Says Completes Acquisition Of Flatiron Health

* SAYS COMPLETES ACQUISITION OF FLATIRON HEALTH Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)

BRIEF-FDA Approves Roche's Lucentis prefilled syringe For Diabetic Macular Edema, Diabetic Retinopathy

* FDA APPROVES GENENTECH’S LUCENTIS (RANIBIZUMAB INJECTION) 0.3 MG PREFILLED SYRINGE FOR DIABETIC MACULAR EDEMA AND DIABETIC RETINOPATHY

Select another date: